Q32 Bio Inc. (NASDAQ: QTTB) announced it has entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants totaling approximately $55 million.

The clinical-stage biotechnology company will issue 6,725,000 shares of common stock at $8.00 per share and pre-funded warrants to purchase 150,000 shares at $7.9999 per warrant. The pre-funded warrants are immediately exercisable and will expire when exercised in full.

The private placement is being led by BVF Partners L.P., with participation from RA Capital Management, OrbiMed, and Atlas Venture. Morgan Stanley served as lead placement agent and Oppenheimer & Co. acted as a placement agent.

The transaction is expected to close on May 28, 2026, subject to customary closing conditions. The gross proceeds will be approximately $55 million before deducting placement agent fees and other offering expenses.

Q32 Bio focuses on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The company is advancing bempikibart, a fully human anti-IL-7Rα antibody, for treating alopecia areata in an ongoing Phase 2 program.

The securities are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933. Q32 Bio has agreed to file a registration statement with the Securities and Exchange Commission for the resale of the shares and shares issuable upon exercise of the pre-funded warrants.